Show simple item record

dc.contributor.authorNichol, Alistair
dc.contributor.authorFrench, Craig
dc.contributor.authorLittle, Lorraine
dc.contributor.authorPresneill, Jeffrey
dc.contributor.authorCooper, D James
dc.contributor.authorHaddad, Samir
dc.contributor.authorDuranteau, Jacques
dc.contributor.authorHuet, Olivier
dc.contributor.authorSkrifvars, Markus
dc.contributor.authorArabi, Yaseen
dc.contributor.authorBellomo, Rinaldo
dc.date.accessioned2016-04-18T14:05:14Zen
dc.date.available2016-04-18T14:05:14Zen
dc.date.issued2015-02-08en
dc.identifier.citationErythropoietin in traumatic brain injury: study protocol for a randomised controlled trial. 2015, 16:39 Trialsen
dc.identifier.issn1745-6215en
dc.identifier.pmid25884605en
dc.identifier.doi10.1186/s13063-014-0528-6en
dc.identifier.urihttp://hdl.handle.net/10147/605742en
dc.description.abstractTraumatic brain injury is a leading cause of death and disability worldwide. Laboratory and clinical studies demonstrate a possible beneficial effect of erythropoietin in improving outcomes in the traumatic brain injury cohort. However, there are concerns regarding the association of erythropoietin and thrombosis in the critically ill. A large-scale, multi-centre, blinded, parallel-group, placebo-controlled, randomised trial is currently underway to address this hypothesis.
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326467/pdf/13063_2014_Article_528.pdfen
dc.rightsArchived with thanks to Trialsen
dc.subjectBRAIN INJURYen
dc.subject.meshAdolescenten
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshBrain Injuriesen
dc.subject.meshClinical Protocolsen
dc.subject.meshData Interpretation, Statisticalen
dc.subject.meshErythropoietinen
dc.subject.meshHumansen
dc.subject.meshMiddle Ageden
dc.subject.meshOutcome Assessment (Health Care)en
dc.subject.meshSample Sizeen
dc.subject.meshThromboembolismen
dc.subject.meshUltrasonography, Doppleren
dc.titleErythropoietin in traumatic brain injury: study protocol for a randomised controlled trial.en
dc.typeArticleen
dc.identifier.journalTrialsen
dc.description.fundingOtheren
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
refterms.dateFOA2018-08-27T13:55:21Z
html.description.abstractTraumatic brain injury is a leading cause of death and disability worldwide. Laboratory and clinical studies demonstrate a possible beneficial effect of erythropoietin in improving outcomes in the traumatic brain injury cohort. However, there are concerns regarding the association of erythropoietin and thrombosis in the critically ill. A large-scale, multi-centre, blinded, parallel-group, placebo-controlled, randomised trial is currently underway to address this hypothesis.


Files in this item

Thumbnail
Name:
ErythropoietinTraumaticBrainIn ...
Size:
579.6Kb
Format:
PDF
Description:
OA Article

This item appears in the following Collection(s)

Show simple item record